NHS Innovation Accelerator (NIA)
The NHS Innovation Accelerator, or NIA, supports uptake and spread of proven, impactful innovations across England’s NHS, benefitting patients, populations and NHS staff.

Ideas (Wellness and prevention of illness)

Innovation 'Elevator Pitch':
ChatHealth is a messaging helpline to enable service users to securely contact a healthcare professional, supporting timely, confidential access to help.
Overview of Innovation:
ChatHealth is a safe and secure text messaging service that helps families and young people get in touch with healthcare professionals. First developed by school nurses at Leicestershire Partnership NHS Trust (LPT), ChatHealth supports greater efficiencies within public health community nursing teams, with individual nurses able to provide for a greater number of service users. It is cost effective and uses technology millennials are familiar with, providing confidential and timely access to
healthcare. People who need health advice and support do not need to wait for a nurse visit and the service is completely anonymous meaning it reaches out to often seldom-heard and vulnerable groups.
  • Available to nearly two million young people in England.
  • Available to the parents/carers of nearly 80,000 new-born babies a year.
  • Increased service reach/access - delivering 100 additional contacts every month.
  • Overcomes the stigma of face-to-face discussion of sensitive issues.
  • Reaches more underserved groups - 1 in 5 male users compared to 1 in 10 in face-to-face clinics.
ChatHealth can help teams to deliver more contacts with existing resources. At any time, just one health care professional can handle all messaging enquiries from an entire population, usually only impacting around 0.5WTE capacity. At a combined cost of £10k (salary and product licensing) less than a WTE post, a single healthcare professional can support a population of 85,000 service users and deliver 50 contacts p.c.m. These low-cost additional contacts eliminate unnecessary face-to-face contact (more resource intensive, more costly to taxpayers). They say it would take four more staff to deliver the same number of additional contacts face-to-face, costing £150k.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
ChatHealth is an efficient way of working for teams that are already stretched, for example one duty nurse can support large populations of people, within existing capacity, delivering up to 100 additional contacts every month. Working in more traditional ways, it would require the appointment of two additional nurses to improve reach to the same level. With the assurance of safety and security in place, ChatHealth offers the followinf benefits to the NHS:
  • More contact from more new service users across a broader range of issues. This is particularly relevant for certain “hard to reach” demographics, such as adolescent males, who are more likely to ask for health advice and help by sending a message compared with traditional forms of service access.
  • ChatHealth is a sustainable solution. Environmentally, it reduces travel, particularly in rural areas where nurses might otherwise drive up to 90 minutes to visit a particular school.
  • Due to how ChatHealth changes the model of delivery, resources can be better allocated and promote more effective spend of taxpayers’ money.
  • Strengthens and complements the universal face to face support offered by Public Health/School Nurses and Health Visitors through a digital offer which could be integrated with other services such as CAMHS, Speech and Language Therapy, nutrition and dietetics.
  • Improved access to healthcare for more children and teenagers/parents and carers who would be to engage directly with health professionals.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Evidence shows that young people sometimes feel more comfortable and confident relaying sensitive issues via mobile technology rather than a face-to-face discussion with a healthcare professional whilst busy parents especially value its convenience. 

The ChatHealth platform is predominantly used by community health teams supporting universal care. The majority of enquiries relate to emotional and mental wellbeing, including adolescent self-harming and low mood and maternal mental health. Some of these kinds of contacts can be significant from the point of view of safeguarding
vulnerable service users and the ChatHealth model helps to safeguard risk. Other regular types of enquiries relate to adolescent sexual health, or new parents enquiring about infant health and development.

Children, young people and families in the West Midlands can expect to gain the following benefits:
  • Improved and more convenient access to the specialist community public health nursing service.
  • Children & young people can contact public health/school nurses during the school holidays.
  • Improved response to need which will lead to earlier intervention.
  • Improved, quick and easy access to health advice and support for children, young people and their families.
  • Swift response to text messages within the core hours of service delivery.
  • User friendly/age appropriate resources that are localised.
  • Targeted provision for more vulnerable young people and adults that may find it difficult to access services.
  • Extends service provision to service users that may have not previously accessed the service.
  • Transcripts of the messages can be copied over to the EPR where a service user has been identified, enriching the patient record. Anonymous transcripts can be downloaded as pdf’s and stored in a secure drive.
Current and planned activity: 
Around 38 NHS Trusts and organisations have adopted ChatHealth, they receive ongoing support for their licences. We are also in discussion with several organisations who are interested in adopting ChatHealth.
What is the intellectual property status of your innovation?:
All intellectual property is held by Leicestershire Partnership NHS Trust.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Laura Serra 09/05/2019 - 16:31 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Digital behaviour change platform for people with type 2 diabetes and prediabetes providing goal-focused education, personalised resources and support to implement a lower carbohydrate lifestyle. 
Overview of Innovation:
The Low Carb Program is an award-winning digital health intervention for people with type 2 diabetes, prediabetes and obesity. The Low Carb Program provides the education, resources, and, most importantly, support required when reducing the amount of sugar (or carbohydrates) in the diet.

The platform is available in the NHS Apps Library and is an NHS Innovation Accelerator Fellow for 2019. The platform is QISMET approved to be provided as structured education for people with type 2 diabetes and prediabetes.
 
The platform comprises:
  • Education: members participate in a core 12-week structured therapeutic nutrition and wellness program, personalised to disease type and profile
  • Community peer support with over 400,000 members
  • Behaviour change mentoring, goal identification and setting
  • Library of personalised resources, including culturally-specific meal plans, food swaps and over 1,000 searchable recipe ideas
  • Data insights and AI-led feedback to support sustainable behaviour change
The Low Carb Program was developed with Dr David Unwin in 2015 (NHS Innovator of the Year 2016, RCGP National Champion for Collaborative Care in Obesity and Diabetes), and the feedback of 20,000 people with diabetes. 

DDM is conducting a three-year study on a randomly selected cohort of people who joined the Low Carb Program. One-year outcomes have been published in JMIR Diabetes with two-year outcomes are currently under review. The first evidenced benefit is a 71% platform retention at 1-year, which is unrivalled for any digital platform. Engagement within the platform is critical as without engaging users, behaviour change is not possible. The retention evidenced by the Low Carb Program is pioneering.
 
For people with type 2 diabetes who complete the platform, outcomes are:
  • 7.4kg weight loss
  • 13mmol/mol HbA1c reduction
  • 39% place HbA1c under type 2 diabetes threshold, with 26% placing type 2 diabetes 'in remission'
Remission is defined as an HbA1c under type 2 diabetes threshold and on no medication or metformin only.
 
In addition, to this:
  • 40% of people on medication eliminate at least one treatment from their regime
  • 60% of people on insulin eliminate or reduce it from their regime
The Low Carb Program has tiered licencing costs, with a patient licence cost of £90, which lasts 3 years. Given the affordability of the platform the Low Carb Program offers significant cost-savings from the perspective of reduced medication through improved patient health and reduced GP burden.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The Low Carb Program is scaling type 2 diabetes and prediabetes remission and benefits are most immediately seen in reduced medication dependency through improved HbA1c. A three-year study is underway on a randomly selected cohort of 1,000 people who joined the Low Carb Program. One-year outcomes have been published in JMIR Diabetes. The first evidenced benefit is a 71% platform retention at 1-year, which is unrivalled for any digital platform. Engagement within the platform is critical as without engaging users, behaviour change is not possible. The retention evidenced by the Low Carb Program is pioneering.
 
For people with type 2 diabetes who complete the platform, outcomes are:
  • 7.4kg weight loss
  • 13mmol/mol HbA1c reduction
  • 39% place HbA1c under type 2 diabetes threshold, with 26% placing type 2 diabetes 'in remission'
Remission is defined as an HbA1c under type 2 diabetes threshold and on no medication or metformin only.
In addition, to this:
  • 40% of people on medication eliminate at least one treatment from their regime
  • 60% of people on insulin eliminate or reduce it from their regime
A conservative cost-saving medication deprescription analysis was conducted on this cohort of users, and calculated at £835 per-patient, per-year in reduced medication deprescription savings.
 
Given the affordability of the platform, particularly when compared to competitors, the Low Carb Program offers significant cost-savings from the perspective of reduced medication through improved patient health and reduced GP burden.

There is clinical evidence of the Low Carb Program in practice, where it is being used with patients by NHS Symphony Healthcare health coaches with patients with type 2 diabetes in Yeovil in a blended care approach.

Currently, clinical data demonstrates improvements in HbA1c and weight for the majority of patients using the platform.
Benefits of engaging within the education are truly brought to life by many of the 400,000 members' stories, including:
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Adoption of the Low Carb Program will significantly improve patient and population health of people with type 2 diabetes and prediabetes in the West Midlands. 

Benefits are most immediately seen in reduced medication dependency through improved HbA1c. A three-year study is underway on a randomly selected cohort of 1,000 people who joined the Low Carb Program. One-year outcomes have been published in JMIR Diabetes. The first evidenced benefit is a 71% platform retention at 1-year, which is unrivalled for any digital platform. Engagement within the platform is critical as without engaging users, behaviour change is not possible. The retention evidenced by the Low Carb Program is pioneering.
 
For people with type 2 diabetes who complete the platform, outcomes are:
  • 7.4kg weight loss
  • 13mmol/mol HbA1c reduction
  • 39% place HbA1c under type 2 diabetes threshold, with 26% placing type 2 diabetes 'in remission'
Remission is defined as an HbA1c under type 2 diabetes threshold and on no medication or metformin only.
In addition, to this:
  • 40% of people on medication eliminate at least one treatment from their regime
  • 60% of people on insulin eliminate or reduce it from their regime
A conservative cost-saving medication deprescription analysis was conducted on this cohort of users, and calculated at £835 per-patient, per-year in reduced medication deprescription savings.
 
Given the affordability of the platform, particularly when compared to competitors, the Low Carb Program offers significant cost-savings from the perspective of reduced medication through improved patient health and reduced GP burden. 
Current and planned activity: 
The Low Carb Program is currently being showcased through the NHS Innovation Accelerator. It is also a member of the RCGP Innovation Mentorship Programme. Ascensia Diabetes Care lead implementation of the Low Carb Program within local areas once commissioned, including on-site healthcare professional training and support, patient onboarding resources and Key Manager 24/7 support. 
What is the intellectual property status of your innovation?:
All copyright and IP belongs to Diabetes Digital Media (DDM). Patents pending.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
ARJUN SINGH PANESAR 25/03/2019 - 13:30 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Kemuri portable K-Sockets have a 500% return on investment in one year.  Use them to accelerate hospital discharge of elderly or frail people into reablement by social services.
Overview of Innovation:

Kemuri K-Sockets are power sockets with multiple sensors that continuously measure:
  • Movement of people in the kitchen;
  • Electrical power for kettles, microwaves or toasters;
  • Room temperature;
  • Power supply.
They send data via the Internet via GSM mobile phone communications.  Kemuri software learns patterns of normal activity and analyses Activities of Daily Living (ADLs) every hour.  As soon as the system identifies too many changes from normal, it automatically alerts people who need to respond to possible risks.  Responders can be families, carers or 24/7 alarm response centres.

The WebApp gives evidence of reablement of the service users.  It gives confidence to responders who have been given informed consent to view the data.  For example:
  • Wandering or unattended falls: Kemuri alerts non-return to kitchen;
  • Nutrition & Hydration: Kemuri alerts risk of dehydration or malnutrition;
  • Engaged the Community: Kemuri apps are free to authorised family, carers or voluntary sector;
  • Active in the home: If people can eat, drink and move around in warm surroundings – then they are performing key ADLs.
Portable K-Sockets are allocated to discharge teams as part of the normal hospital discharge process. Families or other carers have to respond to alerts and determine the action to be taken.  The devices are re-allocated to patients every 6 weeks. Thereafter fixed K-Sockets can be installed in kitchens as wellbeing monitors. 

The cost is less than £500 per year, and the notional saving on bed days is approximately £400 per day.  By using a unit eight times per year, more than £3200 budget is released for more patients.  This represents more than 500% return on investment in one year.  This must be worth a trial in the region.  Additional benefit can come from reduced re-admissions.

Surrey County Council have awarded a grant of £50,000 for measuring the reablement process and subsequent wellbeing monitoring.





 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Two areas of immediate benefit are the saving of excess bed days for non-medical reasons and the avoidance of re-admission. 
  • Many elderly and frail people cannot be safely discharged from hospital without a period of reablement by family members or professional domiciliary carers.  The NHS typically funds this for a maximum of six weeks – at lower cost than the occupation of a hospital bed.  After assessment and transfer of care to social services, continuous monitoring by K-Sockets permits safe discharges a day or more earlier.  This eases the problems of Bed Managers seeking to release beds for new patients.
  • During reablement, automatic alerts warn of unusual changes of activity.  They could indicate the risk of unattended falls, dehydration, malnutrition of hypothermia; all costly to the NHS.  Appropriate action could avoid the need for re-admission.  
Kemuri is designed for both family carers and 24/7 response services.  Portable K-Sockets require zero installation time and do not require broadband.  Monitoring and machine learning starts within minutes and any people with consent for data sharing can immediately view the data or receive alerts.
 
Longer-term benefits come from wellbeing monitoring after reablement.  Portable K-Sockets can be replaced by fixed K-Sockets.  The data analysis could reveal medical problems, such as UTIs, and preventive action could avoid more costly treatments.    
 
Benefit to WM population:
Most older people want to return to their own homes as soon as possible after treatment.  Unfortunately, for some independent people, they cannot be discharged because there is no care provision at home.  Perhaps they have no local family or friends.  Consenting to reablement monitoring by K-Sockets could accelerate their discharge and improve health outcomes. 

Families also obtain peace of mind, whether they live locally or at great distances.  At any time of day, people can be alerted to possible problems and respond appropriately.  Most frequently it may only require a reassuring phone call.  On other occasions it could be an unattended fall or medical event that needs clinical action.  Earlier treatment leads to better health outcomes.

It may be possible to reduce the costs of domiciliary care with more-timely and less frequent visits. 
This is an example screen:



A green day shows normal activity.  An amber day shows more changes from normal activity – but may not be cause for alarm.  Red days are alerted during the day and are a call for action.  Viewers can drill down to more detail, and the screen below could indicate the risk of hypothermia.



K-Sockets are invaluable as passive monitors to supplement active telecare devices, such as pendant alarms.  The latter are not worn continuously by 90% of the people who have them and they need reasonable cognition to use them when necessary.  K-Sockets are not stigmatising and do not require any change of lifestyle.

For more information and downloads see http://www.kemurisense.com
Current and planned activity: 
Cornwall Council is trialling 20 portable K-Sockets for reablement.  In one case, an alert was sent to a family member before they knew about an unattended fall.
 
Surrey County Council have awarded a grant for TECS Innovation.  The plan is to supply 40 portable K-Sockets for reablement and then supply 100 fixed K-Socket to vulnerable people for six months.  Social Care will perform assessments as part of their normal case management.  An anonymised log of each service user should provide evidence of the bed days saved.  Statistics of readmission or transfer to full-time residential care can be compared to current averages.
 
Many K-Sockets are operational in small trials and some are still operational after years of use in private houses and housing association properties.  They could collect data for several years in long-term trials for clinical trials, such as for drugs for relieving the symptoms of dementia.
What is the intellectual property status of your innovation?:
Kemuri has patents pending; GB1417259.7, effective date of 30 September 2014 and PCT/GB2015/000275, International Filing Date of 30 September 2015. 
 
Kemuri, KemuriSense, K-Sockets and K-Fobs are registered trademarks. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Leonard Anderson 28/09/2018 - 16:46 Sign Posted Login or Register to post comments
Innovation 'Elevator Pitch':
RespiraSense demonstrated a potential for 6-12 hours earlier detection of patient deterioration when compared to the standard of care. Putting that into context, for every 30-minute delay in treating Sepsis, increases the risk of mortality by 7%
Overview of Innovation:
RespiraSense is the world's only continuous respiratory rate monitor. Respiratory rate is the earliest and single most sensitive indicator of patient deterioration, more so than heart rate if systolic blood pressure. In fact, 26 breaths per minute are considered the earliest point of divergence between Spo2 and respiratory rate. Giving rise to 12+hours of false security is accurate RR is not measured. 

The standard of care remains the manual counting of breaths per minute, which has been shown to be biased and prone to error. With evidence showing no change in the quality of measurements for over 170 years (1846SirHutchenson) (2017Badawy). 

RespiraSense gives medical teams the advantage of being able to intervene early, thus reducing time to intervention and improving outcomes. Outcomes such as Average Length of Stay, Average Unit Cost of Care, and Patient Safety targets can be achieved. 

RespiraSense is a simple, wireless, and discrete wearable monitor, placed on at admission and worn/measuring continuously for up to 7 days. Each patient receives a new sensor and a reusable electronic device or Lobe. See how the system works @ https://www.youtube.com/watch?v=u6KB1hBPQbM  
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Each year, there are approximately 500,000 admissions of Sepsis and Pneumonia with an average unit cost of £4,600 per admission. These two conditions are increasing in incidence and often lead to an escalation of care due to the risk of undetected deterioration. It's shown that a 5% reduction in the escalation of care of these two pathways alone, through the use of continuous Respiratory Rate monitoring triggering decreased time to interventions (Fluids, Oxygen, Antibiotics, Steroids), can reduce the average unit cost by £300 and the average length of stay by 0.5 days. This translates into a total Net cash saving of £115m and 250K bed days. Popular opinion suggests that as high as 20% reduction is achievable - Evidence pending. 

Each event prevented, having an average cost of £25,000, will pay for a whole year's supply of sensors for one year.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
West Midlands Trusts are driving the awareness of Sepsis through their ambulance services, patient awareness campaigns, and in-hospital initiatives. With 44,000 lives lost each year attributed to Sepsis, it is important to Prevent, Diagnosis Early, and Effectively Treat the condition. RespiraSense focused on the area of Diagnosis Early. Research suggests that NEWS2 is a more sensitive indicator of deterioration due to Sepsis than QSOFA. Both of which have Respiratory Rate as a critical parameter to measure. There is clinical and economical value in monitoring this essential vital sign accurately and clear additional benefit to having it monitored continuously. RespiraSense achieves both with low impact of False alarm due to its innovative design, boasting advanced motion-tolerance. 
Current and planned activity: 
PMD Solutions is working with Nursing Times to launch an educational campaign on the clinical science and importance of respiratory rate monitoring in acute care clinical practice. 

In addition, PMD Solutions is looking for Respiratory and Emergency teams to partner with and create a culture of Peer Leadership in the development of best practice for respiratory rate monitoring. 
What is the intellectual property status of your innovation?:
RespiraSense is positioned to be the new industry standard in respiratory rate monitoring. It is patented in Europe, United States, China, Hong Kong, and Japan. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Myles Murray 02/03/2018 - 21:21 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ORCHA is the world’s largest Health App library ORCHA has been designed to offer local targeted app stores to engage populations and to support professionals to recommend the best apps to their patients.

Overview of Innovation:
ORCHA, the Organisation for the Review of Care and Health Applications, is an SME specialising in the rapidly developing world of health and care mobile applications and related digital health services. The medical and wellbeing app market is growing fast, offering the prospect for clinicians and patients to better monitor, report and manage multiple health challenges. Apps exist and are in development for a wide array of users, ranging from solutions that remind and assist people with essential activities, to approaches that monitor key physiological parameters to improve management of multi-morbid long term conditions and to improve quality of life through enabling social interaction.


 
There is growing evidence that apps can improve outcomes for populations and patients, however, there is currently little independent review to ensure their effectiveness, safety or value to users and professionals. This limits user and professional confidence, the growth of app businesses, and also constrains the opportunity for the UK population to take advantage of apps to address major health demographic issues while potentially reducing load on public resources. The sheer scale of emerging apps in health and care also actively inhibits the use of these services, as patients, carers and their health and care professionals struggle to find the right solutions. Finding a clear and trusted pathway through these congested waters is a critical enabler of any wider digital health strategy.  ORCHA provides the solution. It delivers a clear and robust approach to the review, validation and dissemination of these services and through this core capability creates an attractive powerful and multifaceted digital health hub that patients, carers, health and care professionals and developers themselves are all able to utilise to drive this critical agenda.
 
The ORCHA platform has been designed to consist of multiple ‘white labelled’ variants, which are all driven by a common repository of review information and associated data. Through this approach it is possible to create solutions targeted for particular geographies, conditions or cohorts, enabling the key ORCHA components to be seamlessly integrated into existing public facing and professional facing solutions.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Person centred care
Benefit to NHS:
The key benefit of the ORCHA solution is to individual patients & citizens in supporting them to find solutions they can trust to improve their health & wellbeing & in also supporting clinical professional groups across health & care providers, who wish to recommend, prescribe & clinically implement apps.  We have hundreds of GPs, clinicians & carers who are using this feature to prescribe apps to their patients & clients. For example, we are working with in primary care where local practices are using the system to recommend the best smoking cessation app to their patient lists known to smoke. We are also working with care assistants who prescribe apps as a part of health checks & we are working with Mental health services, where patients are provided with an app at their GP appointment & along the IAPT or CAHMs pathway. Here apps have been seen to reduce patients need for therapy, drugs & have also been used to achieve better outcome measures across the whole pathway.
 
The ORCHA tool is the first scalable assessment of health-apps, enabling clinicians to recommend & end-users to benefit from apps of guaranteed quality & safety. Through research-oriented design, ORCHA enables clinicians & commissioners to provide solutions in areas of unmet need, gauge the opinions/experiences of users & evaluate impact of services against patient-level outcomes. By making evidence central to activities, ORCHA is slowly transforming mHealth, from a largely uncertain prospect, to a valued tool in the armoury of clinicians & patients alike; mitigating risks & improving the likelihood of TECS embedding themselves as valued components of clinical pathways.
 
ORCHA are:
  • Increasing the availability of evidence-based services to those otherwise unable to fully benefit from face-to-face services, enabling care from home & helping the NHS maintain ‘equal access for equal need’
  • Increasing trust among those using & commissioning app-based services, by informing users of the risks & benefits of over 3,500 health-apps to date
  • Working with East Lancashire, West Lancashire, Bolton & Salford health economies to ensure those quitting smoking, still receive adequate support following the reduction or withdrawal of funding for smoking cessation support
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
The key benefit of the ORCHA solution is to individual patients and citizens in supporting them to find solutions they can trust to improve their health and wellbeing and in also supporting clinical professional groups across health and care providers, who wish to recommend, prescribe and clinically implement apps.  We have a growing number of GPs, clinicians and carers who are using this feature to prescribe apps to their patients, and clients.
 
We work at regional and local level to activate populations to access a local library of health apps to support their health or health needs, activate patients through their trusted professional and upskill the professionals communities with a wide range of apps and the ability to prescribe these solutions to create a digital health offering which is reportable, managed and governed.
 
We also support health and care app developers. ORCHA not only provides these individuals and organisations with a ‘route to market’ outside the very crowded and commercially challenging confines of the various major app stores, but it also provides an environment for solution improvement, collaboration and the creation of critical interfaces that not only drive greater interoperability between complimentary solutions, but also starts to enable the creation of shared standards and common protocols around key issues such as data privacy and control.

ORCHA are:
  • Highlighting that working in schools is a viable & sustainable approach to activating young people & their families to use health-apps for health promotion; with the average child registering with ORCHA subsequently recommending 6.4 apps to others, 61% resulting in a download
  • Supporting KS4 students in raising awareness of taboo subjects including sexual/mental health through the use of apps. Students are now using ORCHA to extend their advice to include additional apps (not just period trackers) to attendees of the shool based clinic
  • Enabling North West London CCG to identify barriers to implementing TECS, promote efficiency & extend the effective reach of existing care; gaining user feedback to overcome these barriers & realise the benefits of TECS across North West London
  • Demonstrating, through our academic research published in BMJ:Evidence-based mental health, that contrary to popular belief, app quality is not correlated with both prior download figures & user-review scores, providing prospective app-users with useful information to minimise blind faith in popular apps[3].

 
Current and planned activity: 
Health app activation is a real challenge for health care systems. The ORCHA Solution enables customisable App Libraries that can help you to promote reviewed Apps to a specific population. These tailored App Libraries, “ORCHA Microsites” have been designed to enable them to be configured to meet your specific requirements. ORCHA Pro-Account works with the Microsites & is in essence a prescribing solution for health/care professionals. The service supports organisations that have commissioned App Licenses (an increasing trend) to manage the distribution of licenses by their staff & the ProAccount provides the core infrastructure for managing & monitoring Health App prescribing more broadly. The act of recommending an App via the Pro-Account feature is a key tool where individuals are 10 times more likely to respond positively to a prompt from healthcare professionals than if they arrived on the site via a direct search. Engaging clinical communities is a core feature of our solution.
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Liz Ashall-Payne 27/02/2018 - 13:54 Publish Login or Register to post comments
0
0
Votes
-99999

Recent Activities

My Diabetes My Way has been moved from Initial Submission to Publish 2 days 17 hours ago
My Diabetes My Way has been moved from Detailed Submission to Publish 3 weeks 6 days ago
Scott Thornton voted on ChatHealth 1 month 5 days ago
ChatHealth has been moved from Initial Submission to Publish 1 month 1 week ago
Joanne Mewis commented on Low Carb Program 2 months 3 weeks ago

Active Campaigns